Inhibition of CRM1 activity sensitizes endometrial and ovarian cell lines to TRAIL-induced cell death.

ABSTRACT:

Background

CRM1 enrichment has been shown to be indicative of invasive as well as chemoresistant tumors. On the other hand, TRAIL, a powerful and specific anti-tumoral agent, has yet to be used effectively to treat gynecological tumors in patients. In the present study, we examined if CRM1, a nuclear exporter capable of mediating protein transport, could be a relevant target to restore chemosensitivity in chemoresistant cells. We thus explored the hypothesis that CRM1-driven nuclear exclusion of tumor suppressors could lead to chemoresistance and that CRM1 inhibitors could present a novel therapeutic approach, allowing sensitization to chemotherapeutic agents.

Methods

Ovarian cancer cell lines, as well as endometrial cancer cell lines, were treated with leptomycin B (LMB), c

SUBMITTER: Fabi F 

PROVIDER: S-EPMC6033231 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature